<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149093</url>
  </required_header>
  <id_info>
    <org_study_id>2020-2597</org_study_id>
    <nct_id>NCT04149093</nct_id>
  </id_info>
  <brief_title>The Association Between Calretinin and the Function of Ganglion Cells in Hirschsprung Disease</brief_title>
  <official_title>The Association Between Calretinin and the Function of Ganglion Cells in Long Segment and Total Hirschsprung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the outcomes of patients with long segment Hirschsprung disease or&#xD;
      total colonic aganglionosis who had negative calretinin staining and positive ganglion cells&#xD;
      on the proximal resection margins to those who had both positive findings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term outcomes (Quality of life questionnaire)</measure>
    <time_frame>1 year</time_frame>
    <description>To determine if calretinin has a role in the function of ganglion cells in long segment Hirschsprung disease and total colonic aganglionosis.&#xD;
HAQL (Hirschsprung's disease and Anorectal malformations Quality of Life) questionnaire. For each item the response is scored from 0 to 3 and then, linearly transformed to a 0 (minimum value) to 100 (maximum value) scale. Higher score suggests a better quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>1 year</time_frame>
    <description>Number of reoperations&#xD;
Number of rebiopsies&#xD;
Number of readmissions&#xD;
Number of bowel obstructions&#xD;
Number of bowel perforation&#xD;
Number of anastomotic leaks&#xD;
Number of anastomotic strictures&#xD;
Number of fistula&#xD;
Number of anal stenosis&#xD;
Number of Hirschsprung-associated enterocolitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>Presence of constipation (yes/no)&#xD;
Presence of diarrhea (yes/no)&#xD;
Presence of incontinence and soiling (yes/no)&#xD;
Presence of abdominal distension (yes/no)&#xD;
Presence of dependance on enemas/medications (yes/no)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hirschsprung Disease</condition>
  <condition>Ganglion</condition>
  <condition>Hirschsprung Disease, Long-Segment</condition>
  <condition>Hypoganglionosis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Calretinin staining</intervention_name>
    <description>A paraffin-embedded hematoxylinphloxin-safran sections will be performed on tissue specimens of proximal resection margins to evaluate the presence or absence of ganglion cells.&#xD;
Immunohistochemistry (IHC) will then be done on paraffin-embedded sections for calretinin staining.</description>
    <other_name>Immunohistochemistry</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Hirschsprung disease and a transition zone more proximal to the distal&#xD;
        sigmoid&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed histopathological diagnosis of Hirschsprung disease from January 1, 1990 to&#xD;
             August 31, 2019&#xD;
&#xD;
          -  Long-segment Hirschsprung disease (type A and B)&#xD;
&#xD;
          -  Total colonic aganglionosis (TCA)&#xD;
&#xD;
          -  Surgery at CHUSJ&#xD;
&#xD;
          -  Tissue blocks of proximal resection margin available for pathological analysis&#xD;
&#xD;
          -  Minimum 1 month of postoperative follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Short-segment Hirschsprung disease (conventional form, rectosigmoid junction)&#xD;
&#xD;
          -  Total colonic with small bowel aganglionosis (TCSA)&#xD;
&#xD;
          -  Surgery done at another institution&#xD;
&#xD;
          -  Early deaths&#xD;
&#xD;
          -  Lost to follow-up&#xD;
&#xD;
          -  No documented post-operative outcome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Le-Nguyen, MD</last_name>
      <phone>5146929694</phone>
      <email>annie.le-nguyen@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Nelson Piche</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganglion Cysts</mesh_term>
    <mesh_term>Synovial Cyst</mesh_term>
    <mesh_term>Hirschsprung Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

